Digests

Decision Information

Decision Content

PATENTS

Practice

Eli Lilly Canada Inc. v. Canada (Minister of Health)

T-1918-00

2002 FCT 1248, Layden-Stevenson J.

2/12/02

15 pp.

Judicial review of Minister's decision to remove "Compudose" implants patent from register--Whether Minister erred in finding "Compudose" not medicine or use of medicine under Patented Medicines (Notice of Compliance) (NOC) Regulations--"Compudose" controlled release implant used to increase weight gain in livestock--Implant comprised of silicon matrix containing hormone estradiol--Hoffmann-La Roche Ltd. v. Canada (Minister of National Health and Welfare) (1995), 62 C.P.R. (3d) 58 (F.C.T.D.); affd (1995), 67 C.P.R. (3d) 25 (F.C.A.) distinguished--Argument meaning of "medicine" in NOC Regulations, s. 2 should be determined by reference to Food and Drugs Act (FDA) definition of "drug" in so far as relates to paragraph (b) of FDA definition, without merit--Nothing in NOC Regulations generally or in NOC definition of "medicine" contemplating described use-- Regardless, applying principles of patent construction in Free World Trust v. Électro Santé Inc., [2000] 2 S.C.R. 1024 patent claims relate to implant, method of preparing implant, not to claim for medicine or use of medicine--Application dismissed --Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, s. 2 "medicine"--Food and Drugs Act, R.S.C., 1985, c. F-27, s. 2 "drug" (as am. by S.C. 1993, c. 34, s. 71).

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.